Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Brain & Neurology

The Effects of Light Therapy on Cognitive Function and Stress in Women With Breast Cancer Before Systemic Treatment

Overall, these findings suggest that light therapy may help mitigate the adverse effects associated with BC surgery on CRCI and intrusive thoughts, although further research is warranted.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

In this double-blind randomized trial, women with breast cancer after surgery received blue light or dim light for four weeks. The authors report no group differences in overall cognitive performance or biological stress markers, and fewer cognitive complaints in the blue light group, though the authors call for further research.

Who or what was studied
Women with breast cancer after surgery, before systemic treatment, in a national Icelandic cohort
Limits stated in the abstract
Several secondary findings were non-significant trends (p < 0.11), and the authors state further research is warranted.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

Background

Cancer-related cognitive impairment (CRCI), for example, impairments in reaction time, processing speed, memory and executive function, may be associated with breast cancer (BC) surgery which can disrupt biological and psychological stress markers. Evidence suggests that light therapy may ameliorate cognitive impairment and stress. In this double-blind, randomized controlled trial, we investigated the efficacy of light therapy on mitigating the impact of BC surgery on CRCI in a national Icelandic cohort of women with BC.

Methods

Participants were randomly allocated to receive circadian-effective blue light (BL, N = 60) or circadian-ineffective dim light (DL, N = 57) for 4 weeks after surgery. The primary outcome was overall cognitive performance (assessed via global composite score), and secondary outcomes were specific cognitive domains, cognitive complaints, psychological (depressive symptoms, overall cancer-related stress and its symptoms: hyperarousal, avoidance, and intrusive thoughts) and biological (cortisol and α-amylase) stress markers. Linear regression and path analyses within structural equation modeling frameworks were conducted, adjusted for baseline cognitive performance, age, education, subsequent cancer treatment, cancer stage, and treatment credibility.

Results

No group differences were found in overall cognitive performance or in specific cognitive domains, except for a non-significant trend for faster reaction times in the BL group (p < 0.11). Additionally, the BL group reported significantly fewer cognitive complaints compared with the DL group (p < 0.05), as well as a non-significant trend for less intrusive thoughts (p < 0.11). No group differences were observed in the biological stress markers.

Conclusion

Overall, these findings suggest that light therapy may help mitigate the adverse effects associated with BC surgery on CRCI and intrusive thoughts, although further research is warranted.

Trial Registration

NCT04418856.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Randomized controlled trial, Trial registration, Primary outcome. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies

Brain & Neurology

A multimodal evaluation of transcranial photobiomodulation in mild cognitive impairment: Cognitive, metabolic, and neuroimaging outcomes of a pilot randomized controlled trial

Cognitive, metabolic, and network-level findings are consistent with enhanced mitochondrial efficiency and anti-inflammatory effects. These results support larger, double-blind, multicenter trials to evaluate tPBM as a mitochondria-targeted therapy in early ADRD.

Trial · June 3, 2026 · Rashidi-Ranjbar N et al.